SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scott_jiminez who wrote ()6/28/2000 11:35:00 AM
From: scott_jiminez   of 278
 
I'm trying to organize some thoughts on broad issues in the field. This will eventually be presented here. Unfortunately the process requires reading a multitude of primary articles since there are no review journals nor newsletters which accurately portray the outlook for CNS biotech companies. Wishful thinking and/or ignorance of neuroscience is the usual product of the investor-directed newsletters I've read.

It goes without saying that for the foreseeable future (~10 years), any products for the major CNS maladies will be palliative at best. And as more genetic information becomes available, an appreciation of the incredible complexity these diseases will become manifest.

So while big pharmas may want to munch in this field, and many supposedly well informed biotech poets will look with desire at the aging population and their neurological destiny, it is incumbent upon nascent investors to beware: the brain is very, VERY poorly understood and remedies for Alzheimer's, Parkinson's, and Schizophrenia (to name a few), are a very VERY long way off. These pathologies assuredly have multiple biological AND environmental origins: correcting a single receptor/neurotransmitter/ion channel/second messenger will NOT fix the problem and (in the case of AD and PD for example) does nothing to interrupt the underlying degeneration.

Beware of charlatans with Ph.D.s. The CNS side of biotech is unlikely to reap a harvest for decades. CNS companies will be the loss leaders of biotechs for an extended period; if anyone states otherwise they simply don't know neurobiology.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News